

What is claimed is:

1. A method for screening for anti-thrombotic/anti-platelet activity comprising:

5 a) contacting platelets *in vitro* with a compound to be tested for potential anti-thrombotic/anti-platelet activity; and

b) monitoring the ability of said compound to inhibit thrombin-induced platelet aggregation through inhibition of GP Ib, PAR-1 or PAR-4 receptor binding, wherein
10 the ability to inhibit GP Ib, PAR-1 or PAR-4 binding is indicative of anti-thrombotic/anti-platelet activity of the compound.

2. A method for screening for anti-thrombotic/anti-platelet activity comprising:

15 a) contacting platelets *in vitro* with a compound to be tested for potential anti-thrombotic/anti-platelet activity; and

b) monitoring the ability of said compound to inhibit thrombin-induced platelet aggregation through
20 inhibition of α -thrombin, β -thrombin, or γ -thrombin pathways wherein the ability to inhibit α -thrombin, β -thrombin, or γ -thrombin pathways is indicative of anti-thrombotic/anti-platelet activity of the compound.